🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Measles, Mumps, Rubella and Varicella

Found 88 matching trials

Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)

PHASE3

This study will determine whether participants who receive the vaccine V419...

Status

Completed

Location

Multiple Locations

Start Date

2011-05-26

Trial ID

NCT01341639

Treatments Being Tested

V419 INFANRIX™ hexa RotaTeq Prevenar 13 ProQuad™

A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age

PHASE2

The purpose of this study is to assess immune response and safety of variou...

Status

Completed

Location

GSK Investigational Site

Start Date

2022-02-03

Trial ID

NCT05084508

Treatments Being Tested

Investigational varicella vaccine low potency Investigational varicella vaccine medium potency Investigational varicella vaccine high potency Licensed varicella vaccine Lot 1 Licensed varicella vaccine Lot 2 Measles, mumps, and rubella vaccine Hepatitis A vaccine 13-valent pneumococcal conjugate vaccine

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

PHASE3

The purpose of this study is to evaluate the immunogenicity and safety of G...

Status

Completed

Location

GSK Investigational Site

Start Date

2014-08-25

Trial ID

NCT02184572

Treatments Being Tested

Priorix M-M-R II Varivax Havrix Prevnar 13

Safety Study of ProQuad® rHA in Infants (V221-037)

PHASE3

Primary objective: To describe the safety profile of a second dose of ProQu...

Status

Completed

Location

Multiple Locations

Start Date

2007-10-24

Trial ID

NCT00560755

Treatments Being Tested

ProQuad®

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

PHASE3

The study is being conducted to demonstrate that V221 may be administered c...

Status

Completed

Location

Multiple Locations

Start Date

2006-03

Trial ID

NCT00109343

Treatments Being Tested

Comparator: ProQuad™ (V221)Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)

Bioarray for the Serological Assessment of Immunity Against Vaccine-preventable Infections

N/A

Recent observations in Germany revealed above-average high proportions of r...

Status

Unknown

Location

Center for Infectious Diseases and Infection Control, Jena University Hospital

Start Date

2017-04-01

Trial ID

NCT03107312

Treatments Being Tested

Single blood sample collection

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

PHASE3

The purpose of this study is to evaluate consistency in terms of the immune...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-11-09

Trial ID

NCT01702428

Treatments Being Tested

Priorix M-M-R II Varivax Havrix Prevnar 13

Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

PHASE3

The purpose of this study is to assess the immunogenicity and safety of GSK...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-02-06

Trial ID

NCT01506193

Treatments Being Tested

PriorixTetra™Meningitec

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

PHASE3

The purpose of this clinical study is to evaluate the safety and immunogeni...

Status

Completed

Location

Hvidovre Hospital ( Site 0003)

Start Date

2019-08-28

Trial ID

NCT04016714

Treatments Being Tested

V114 Prevenar 13™Vaxelis™M-M-R®II VARIVAX™

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age

PHASE3

The purpose of this study is to assess how well-tolerated GSK's investigati...

Status

Recruiting

Location

GSK Investigational Site

Start Date

2024-11-26

Trial ID

NCT06693895

Treatments Being Tested

Investigational varicella vaccine Marketed varicella vaccine Measles, mumps, and rubella vaccine Hepatitis A vaccine PCV (pneumococcal conjugate vaccine) 13 PCV 20 Vaxneuvance

Previous Next